Condition Directory

Type 2 Diabetes clinical trials

Directory of U.S. ClinicalTrials.gov public records for Type 2 Diabetes. Browse Type 2 Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3775

Shown on this page

Current sort

How Type 2 Diabetes studies are organized in the registry

Type 2 diabetes records also appear under generic “diabetes” and the abbreviation T2DM, so checking both phrasings gives fuller coverage. The portfolio spans drug trials, lifestyle programs, and large cardiovascular-outcome studies; the study-type filter separates the observational cohorts from interventional trials.

Terms that often appear in related listings

T2DM metformin cardiovascular outcomes lifestyle intervention

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 241–252 of 3,775 matching trials for Type 2 Diabetes.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more

Conditions: Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
Interventions: Calcium-HMB Plus Vitamin D3, Matching placebo; Dietary Supplement · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions: MODI Algorithm; Device
Lead sponsor: DreaMed Diabetes; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: BMF-219; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more

Conditions: Type 2 Diabetes
Interventions: Family Model Diabetes Self-Management Education and Support; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Springdale, Arkansas

Conditions: Type 2 Diabetes
Interventions: icovamenib 100mg, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Canoga Park, California • Fountain Valley, California + 15 more

Conditions: Healthy Participants
Interventions: Elecoglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Type 2 Diabetes
Interventions: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes, Mild Cognitive Impairment
Interventions: Continuous Glucose Monitor (CGM); Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 65 Years to 100 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair; Industry
Eligibility: 24 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Diabetes Mellitus Type 2
Interventions: Harnessing Online Peer Education; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Colorectal Cancer Screening, Diabetes Mellitus, Type 2
Interventions: Targeted CRC Screening Toolkit; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 50 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

About this Type 2 Diabetes clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Type 2 Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Type 2 Diabetes.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Type 2 Diabetes clinical trials

How Type 2 Diabetes studies are organized in the registry

Filter and sort this condition

Live official records

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

Family Model Diabetes Self-Management Education in Faith Based Organizations

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

HOPE Intervention for Fitness

Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings

About this Type 2 Diabetes clinical trials directory page